The cardioprotective effects of SGLT2 inhibitors in patients with heart failure with low ejection fraction appear to be related to improved endothelial function and vasodilatation, reduced inflammation, enhanced diuresis, and improved myocardial metabolism and efficiency [26]. Here, SLC5A2 is linked to heart failure.